Secondary Schizophrenia (158 page)

bipolar I or II depression. Am J

Kramer M.,
et al.
Rapid antimanic
12-week study of quetiapine,

Psychiatry, 2005.
162
:1351–
effect of risperidone

risperidone or fluphenazine on

60.

monotherapy: a 3-week

sexual functioning in people with

30. Chengappa K. N., Goldstein J. M.,

multicenter, double-blind,

schizophrenia. Psycho-

Greenwood M.,
et al.
A post hoc
placebo-controlled trial.

neuroendocrinology, 2006.

analysis of the impact on hostility

Am J Psychiatry, 2004.
161
:
31
:340–6.

and agitation of quetiapine and

1057–65.

46. Daniel D. G., Zimbroff D. L.,

haloperidol among patients with

39. Currier G. W., Chou J. C., Feifel

Potkin S. G.,
et al.
Ziprasidone
schizophrenia. Clin Ther, 2003.

D.,
et al.
Acute treatment of

80 mg/day and 160 mg/day in the

25
:530–41.

psychotic agitation: a randomized

acute exacerbation of

31. Kim K. Y., Bader G. M., Kotlyar

comparison of oral treatment with

schizophrenia and schizoaffective

V.,
et al.
Treatment of delirium in
risperidone and lorazepam versus

disorder: a 6-week

older adults with quetiapine.

intramuscular treatment with

placebo-controlled trial.

J Geriatr Psychiatry Neurol, 2003.

haloperidol and lorazepam. J Clin

Ziprasidone Study Group.

16
:29–31.

Psychiatry, 2004.
65
:386–94.

Neuropsychopharmacology, 1999.

32. Reddy S., Factor S. A., Molho E.

40. McCracken J. T., McGough J.,

20
:491–505.

S.,
et al.
The effect of quetiapine
Shah B.,
et al.
Research units on
47. Keck P. E. Jr., Versiani M., Potkin
on psychosis and motor function

pediatric psychopharmacology

S.,
et al.
Ziprasidone in Mania
in parkinsonian patients with and

autism network. Risperidone in

Study Group. Ziprasidone in the

without dementia. Mov Disord,

children with autism and serious

treatment of acute bipolar mania:

2002.
17
:676–81.

behavioral problems. New Eng J

a three-week, placebo-controlled,

33. Fernandez H. H., Trieschmann M.

Med, 2002.
347
:314–21.

double-blind, randomized trial.

E., Burke M. A.,
et al.
Quetiapine
41. Fontaine C. S., Hynan L. S., Koch

Am J Psychiatry, 2003.
160
:741–
for psychosis in Parkinson’s

K.,
et al.
A double-blind

8.

disease versus dementia with

comparison of olanzapine versus

48. Daniel D. G., Potkin S. G., Reeves
Lewy bodies. J Clin Psychiatry,

risperidone in the acute treatment

K. R.,
et al.
Intramuscular (IM)
2002.
63
:513–15.

of dementia-related behavioral

ziprasidone 20 mg is effective in

402

Chapter 32 – Drug treatment of secondary schizophrenia

reducing acute agitation

57. Schneider L. S., Tariot P. N.,

65. Morgante L., Epifanio A., Spina

associated with psychosis: a

Dagerman K. S.,
et al.

E.,
et al.
Quetiapine versus

double-blind, randomized trial.

Effectiveness of atypical

clozapine: a preliminary report of

Psychopharmacology, 2001.

antipsychotic drugs in patients

comparative effects on

155
:128–34.

with Alzheimer’s disease. N Engl J

dopaminergic psychosis in

Med, 2006.
355
:1525–38.

patients with Parkinson’s disease.

49. Tandon R., Harrigan E, Zorn S.

Neurol Sci, 2002.
23
(Suppl 2):
Ziprasidone: a novel antipsychotic

58. Mintzer J., Greenspan A., Caers I.,
S89–90.

with unique pharmacology and

et al.
Risperidone in the treatment
therapeutic potential. J Serotonin

of psychosis of Alzheimer disease:

66. Prohorov T., Klein C., Miniovitz

Res, 1997.
4
:159–77.

results from a prospective clinical

A.,
et al.
The effect of quetiapine
trial. Am J Geriatr Psychiatry,

in psychotic Parkinsonian

50. Weiden P. J., Iqbal N.,

2006.
14
:280–91.

patients with and without

Mendelowitz A. J.,
et al.
Best

dementia. An open-labeled study

clinical practice with ziprasidone:

59. Schneider L. S., Dagerman K.,

utilizing a structured interview.

update after one year of

Insel P. S. Efficacy and adverse

J Neurol, 2006.
253
:171–5.

experience. J Psychiatr Pract,

effects of atypical antipsychotics

2002.
8
:81–98.

for dementia: meta-analysis of

67. Merims D., Balas M., Peretz C., et
randomized, placebo-controlled

al. Rater-blinded, prospective

51. Kane J., Honigfeld G., Singer J.,

trials. Am J Geriatr Psychiatry,

comparison: quetiapine versus

et al.
Clozapine for the

2006.
14
:191–210.

clozapine for Parkinson’s disease

treatment-resistant schizophrenic:

psychosis. Clin Neuropharma-

a double-blind comparison with

60. Ballard C., Waite J. The

cology, 2006.
29
:331–7.

chlorpromazine. Arch Gen

effectiveness of atypical

Psychiatry, 1988.
45
:789–96.

antipsychotics for the treatment of

68. Klein C., Prokhorov T., Miniovich

aggression and psychosis in

A.,
et al.
Long-term follow-up

52. Suppes T., Webb A., Paul B.,
et al.

Alzheimer’s disease. Cochrane

(24 months) of quetiapine

Clinical outcome in a randomized

Database Syst Reviews, 2006.

treatment in drug-induced

1-year trial of clozapine versus

CD003476.

Parkinson disease psychosis. Clin

treatment as usual for patients

Neuropharmacology, 2006.
29
:
with treatment-resistant illness

61. Alexopoulos G. S., Jeste D. V.,

215–19.

and a history of mania. Am J

Chung H.,
et al.
The expert

Psychiatry, 1999.
156
:1164–9.

consensus guideline series.

69. Ondo W. G., Tintner R., Voung K.

Treatment of dementia and its

D.,
et al.
Double-blind,

53. Green A. I., Tohen M., Patel J. K.,
behavioral disturbances.

placebo-controlled, unforced

et al.
Clozapine in the treatment
Introduction: methods,

titration parallel trial of

of refractory psychotic mania. Am

commentary, and summary.

quetiapine for dopaminergic-

J Psychiatry, 2000.
157
:982–6.

Postgrad Med, 2005. Spec

induced hallucinations in

54. Kant R., Chalansani R.,

No:6–22.

Parkinson’s disease. Mov Disord,

Chengappa K. N.,
et al.
The

62. Pollak P., Tison F., Rascol O.,

2005.
20
:958–63.

off-label use of clozapine in

et al.
Clozapine in drug induced
70. Ellis T., Cudkowicz M. E., Sexton

adolescents with bipolar disorder,

psychosis in Parkinson’s disease: a

P. M.,
et al.
Clozapine and

intermittent explosive disorder, or

randomised, placebo controlled

risperidone treatment of

posttraumatic stress disorder.

study with open follow up. J

psychosis in Parkinson’s disease.

J Child Adol Psychopharmacol,

Neurol Neurosurg Psychiatry,

J Neuropsychiatry Clin Neurosci,

2004.
14
:57–63.

2004.
75
:689–95.

2000.
12
:364–9.

55. Fava M. Psychopharmacologic

63. The Parkinson Study Group.

71. Breier A., Sutton V. K., Feldman P.

treatment of pathologic

Low-dose clozapine for the

D.,
et al.
Olanzapine in the

aggression. Psychiatric Clin N Am,

treatment of drug-induced

treatment of dopamimetic-

1997.
20
:427–51.

psychosis in Parkinson’s disease.

induced psychosis in patients with

56. Spivak B., Mester R., Abesgaus J.,
N Engl J Med, 1999.
340
:757–
Parkinson’s disease. Biol

et al.
Clozapine treatment for

63.

Psychiatry. 2002.
52
:438–45.

neuroleptic-induced tardive

64. Morgante L., Epifanio A., Spina

72. Gonzalez-Heydrich J., Pandina G.

dyskinesia, parkinsonism, and

E.,
et al.
Quetiapine and clozapine
J., Fleisher C. A.,
et al.
No seizure
chronic akathisia in schizophrenic

in parkinsonian patients with

exacerbation from risperidone in

patients. J Clin Psychiatry, 1997.

dopaminergic psychosis. Clin

youth with comorbid epilepsy and

58
:318–22.

Neuropharmacol, 2004.
27
:153–6.

psychiatric disorders: a case series.

403

Treatment – Section 5

J Child Adol Psychopharmacol,

psychosis. HNRC group.

retrospective review. J Geriatr

2004.
14
:295–310.

Neuropsychopharmacology, 1994.

Psychiatry Neurol, 1997.

73. Langosch J. M., Trimble M. R.

10
:223–9.

10
:63–6.

Epilepsy, psychosis and clozapine.

82. Dolder C. R., Patterson T. L., Jeste
92. Juncos J. L., Roberts V. J., Evatt M.

Hum Psychopharmacol, 2002.

D. V. HIV, psychosis and aging:

L.,
et al.
Quetiapine improves

17
:115–19.

past, present and future. AIDS,

psychotic symptoms and

74. Ishii R., Canuet L., Iwase M.,
et al.

2004.
18
(Suppl 1):S35–4.

cognition in Parkinson’s disease.

Right parietal activation during

83. Foster R., Olajide D., Everall I. P.

Mov Disord, 2004.
19
:29–35.

delusional state in episodic

Antiretroviral therapy-induced

93. Fernandez H. H., Trieschmann M.

interictal psychosis of epilepsy: a

psychosis: case report and brief

E., Burke M. A.,
et al.
Long-term

report of two cases. Epilepsy Beha,

review of the literature. HIV Med,

outcome of quetiapine use for

2006.
9
:367–72.

2003.
4
:139–44.

psychosis among Parkinsonian

75. Oner O., Unal O., Deda G. A case

84. Rosenblatt A., Leroi I.

patients. Mov Disord, 2003.

of psychosis with temporal lobe

Neuropsychiatry of Huntington’s

18
:510–14.

epilepsy: SPECT changes with

disease and other basal ganglia

94. Reddy S., Factor S. A., Molho E.

treatment. Pediatr Neurol, 2005.

disorders. Psychosomatics, 2000.

S.,
et al.
The effect of quetiapine

32
:197–200.

41
:24–30.

on psychosis and motor function

76. Brewerton T. D. The

85. Bonelli R. M., Wenning G. K.

in parkinsonian patients with and

phenomenology of psychosis